Related Experiment Video
Updated: Mar 12, 2026
06:13
The Intra-Aortic Balloon Pump
Published on: February 5, 2021
25.6K
Cardiogenic shock: Inotropes and vasopressors
José Amado1, Paula Gago1, Walter Santos1
1Serviço de Cardiologia, Centro Hospitalar do Algarve, Faro, Portugal.
Summary
Cardiogenic shock treatment with inotropes and vasopressors is controversial. This review proposes a therapeutic scheme based on hemodynamic profiles to optimize outcomes for patients experiencing cardiogenic shock.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiogenic shock involves decreased myocardial contractility and high mortality.
- Inotropic and vasopressor agents are standard treatments but remain controversial due to potential side effects.
Purpose of the Study:
- To review current data on inotropes and vasopressors in cardiogenic shock.
- To propose a therapeutic scheme for pharmacological management based on hemodynamic profiles.
Main Methods:
- Systematic review of studies on inotropic and vasopressor use in cardiogenic shock.
- Integration of pharmacodynamic data and clinical outcomes.
Main Results:
- Inotropic therapy can improve contractility but carries risks like arrhythmias and increased oxygen demand.
- Differences in agent pharmacodynamics have not consistently translated to reduced mortality.
- Current evidence makes definitive treatment recommendations challenging.
Conclusions:
- A tailored therapeutic approach is needed for cardiogenic shock.
- Pharmacological treatment should be guided by the patient's specific hemodynamic profile.
- Further research is needed to clarify optimal agent selection and timing.
More Related Videos
06:10Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Published on: June 12, 2021
3.7K
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
4.2K
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
1.7K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.7K
01:24Blood Pressure Imbalances and Circulatory Shock
1.8K
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
1.8K
01:22Heart Failure Drugs: β-Blockers
1.1K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.1K
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
1.2K
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
1.2K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
01:30Heart Failure V: Medical Management
455
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
455